The intersectoral platform is part of the National Pandemic Cohort Network (NAPKON) and will be used to provide a comprehensive and harmonized collection of data and biomaterial for researchers from national consortia, pharmaceutical companies and for participation in international research collaborations for the purpose of studying COVID-19 disease and future pandemics.
The intersectoral platform is part of the National Pandemic Cohort Network (NAPKON), which, together and in interaction with other components of the National Research Network of University Medicine on COVID-19 (NUM), provides the essential basis for the successful understanding and thus combating pandemics using the example of coronavirus disease 2019 (COVID-19). NAPKON represents a sustainable, integrative and comprehensive concept that provides benefits for society as a whole in defending against and coping with pandemics, especially at the level of public health care, in hospital and patient management and from the individual patient's perspective. The intersectoral platform records data and biomaterial of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-infected patients through a network of university clinics, hospitals at all levels of care, general practitioners and specialist practices with appropriate study experience and infrastructure. The longitudinal phenotyping programme tracks patients for up to one year and collects detailed and harmonized clinical data as well as biomaterial. Follow-up data is enriched by patient-reported outcomes (PROM) and recruitment is intensified by focusing on hot-spot regions. Mobile study teams are used to reach, among others, long-term care and rehabilitation facilities, thus mapping all structural elements of the German care network. The primary aim of the intersectoral platform is to provide a comprehensive and harmonized collection of data and biomaterial for researchers from national consortia, pharmaceutical companies and for participation in international research collaborations for the purpose of studying COVID-19 disease and future pandemics.
Study Type
OBSERVATIONAL
Enrollment
6,550
Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
Longitudinal collection of data and biomaterial
To provide a comprehensive and harmonised collection of data and biomaterial for researchers from national consortia, pharmaceutical companies and for participation in international research collaborations for the purpose of studying COVID-19 and future pandemics.
Time frame: day 1 of enrollment in the study, immediately before discharge, 3 and 12 months after diagnosis
Number of cases of SARS-CoV-2 infection
Determine the number of cases of SARS-CoV-2 according to: * Severity of the disease * Deaths * Treatment status * Lengths of hospitalization * Duration of oxygen therapy * Underlying disease
Time frame: 12 months
Changes in concentration of inflammatory parameters.
The changes of inflammatory parameters such as C-reactive protein (CRP) \[mg/l\], will be recorded and evaluated at all visits during the acute phase, if provided.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in concentration of cardiac parameters.
The changes of Fibrinogen \[µmol/l\] will be recorded and evaluated at all visits during the acute phase, if provided.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in concentration of urine parameters.
The changes in concentration of urine parameters such as Albumine (\[mg/g Creatinin\], will be recorded and evaluated, if provided.
Time frame: Assessment of the urine parameters will be performed at all visits during the acute phase until discharge or death, assessed up to 12 months
Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
RWTH Aachen
Aachen, Germany
NOT_YET_RECRUITINGUniversity Hospital Augsburg
Augsburg, Germany
NOT_YET_RECRUITINGCharité Berlin
Berlin, Germany
RECRUITINGKlinikum Bielefeld
Bielefeld, Germany
NOT_YET_RECRUITINGUniversity Hospital Ruhr-University Bochum
Bochum, Germany
NOT_YET_RECRUITINGUniversity Hospital Bonn
Bonn, Germany
NOT_YET_RECRUITINGUniversity Hospital Cologne
Cologne, Germany
NOT_YET_RECRUITINGUniversity Hospital Carl Gustav Carus Dresden
Dresden, Germany
NOT_YET_RECRUITINGUniversity Hospital Dusseldorf
Düsseldorf, Germany
NOT_YET_RECRUITINGUniversity Hospital Erlangen
Erlangen, Germany
NOT_YET_RECRUITING...and 24 more locations
Health related quality of life after hospital discharge will be assessed with the questionnaire European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l)
Time frame: Date of admission, immediately before discharge, 3, 6, 12 months after first diagnosis
Changes in body temperature.
Assessment of the patient´s body temperature will be performed at all visits during the acute phase.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in blood pressure.
Assessment of the patient´s blood pressure will be performed at all visits during the acute phase.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in heart rate.
Assessment of the patient´s heart rate will be performed at all visits during the acute phase.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in breath frequency.
Assessment of the patient´s breath frequency will be performed at all visits during the acute phase.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months
Changes in peripheral oxygen saturation.
Assessment of the patient´s peripheral oxygen saturation will be performed at all visits during the acute phase.
Time frame: Assessement at each study visit until discharge or death, assessed up to 12 months